US$ 25.39
setmelanotide vs semaglutide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial Aqueous remote loading of setmelanotide
Description
Baraboi ED, Smith P, Ferguson AV, Richard D

Metabolic rate, starting weight, and existing dietary habits also shape first-month outcomes

phase RCT with N = 1000) Vicardostat (previously known as BI 690517) in DM & non DM CKD (EASiKidney, phase 3 RCT, N = 11000 of vicardostat + empagliflozin) Different mechanisms of MR antagonists and ASI
Never double doses to make up for a missed dose
(5) for compounded products, the licensed compounding pharmacy and its current regulatory status
A little stomach pain one day, a bit worse the next, and tolerable but annoying by the third day can create a sense of complacency
